| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1047140338 |
| P356 | DOI | 10.1038/LEU.2016.104 |
| P3181 | OpenCitations bibliographic resource ID | 2024912 |
| P932 | PMC publication ID | 4991363 |
| P698 | PubMed publication ID | 27121688 |
| P50 | author | Kimmo Porkka | Q51782104 |
| Andreas Hochhaus | Q37829812 | ||
| Delphine Rea | Q46399398 | ||
| P2093 | author name string | R Hehlmann | |
| D-W Kim | |||
| G Rosti | |||
| J L Steegmann | |||
| H J Khoury | |||
| J Mayer | |||
| M Breccia | |||
| R E Clark | |||
| M Baccarani | |||
| S Saussele | |||
| T D Kim | |||
| V García-Gutiérrez | |||
| L F Casado | |||
| D Milojkovic | |||
| P Le Coutre | |||
| P2860 | cites work | Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib | Q51474966 |
| Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients | Q51604310 | ||
| Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib | Q52884682 | ||
| Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia | Q53156805 | ||
| Retrospective multicenter study on the development of peripheral lymphocytosis following second‐line dasatinib therapy for chronic myeloid leukemia | Q53432205 | ||
| Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome | Q54355007 | ||
| Severe peripheral arterial disease during nilotinib therapy | Q54419090 | ||
| Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis | Q54446241 | ||
| Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients | Q54499425 | ||
| Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up | Q54504324 | ||
| Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. | Q54586024 | ||
| Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives | Q38101884 | ||
| Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy | Q38101885 | ||
| Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect? | Q38161155 | ||
| Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia | Q38392679 | ||
| The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia | Q39229989 | ||
| Tuberculous and non-tuberculous granulomatous lymphadenitis in patients receiving imatinib mesylate (glivec) for metastatic gastrointestinal stromal tumor | Q39636564 | ||
| The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity | Q39741862 | ||
| Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report. | Q40229471 | ||
| Hemorrhagic colitis caused by dasatinib following cytomegalovirus enterocolitis in a patient with chronic myelogenous leukemia in the second chronic phase | Q40322600 | ||
| Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial | Q40807968 | ||
| Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. | Q41668621 | ||
| Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis | Q41857102 | ||
| Dasatinib inhibits proinflammatory functions of mature human neutrophils | Q41885572 | ||
| Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy | Q41892625 | ||
| Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results | Q41899882 | ||
| Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease | Q42015762 | ||
| Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase | Q42276725 | ||
| Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy | Q42323680 | ||
| Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial | Q42613611 | ||
| Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. | Q42621930 | ||
| Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia | Q42867411 | ||
| The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia | Q42958720 | ||
| Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia | Q43043759 | ||
| Relative hypocalcaemia and muscle cramps in patients receiving imatinib for gastrointestinal stromal tumour. | Q43056046 | ||
| Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion | Q43092618 | ||
| Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors | Q43182188 | ||
| Peripheral neuropathy on imatinib treatment for chronic myeloid leukaemia: suspected adverse drug interaction with amlodipine | Q43256707 | ||
| Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia | Q43262982 | ||
| Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily | Q43278551 | ||
| Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors | Q43296843 | ||
| Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes | Q43628935 | ||
| Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors | Q43671220 | ||
| Multiple eruptive dermatofibromas related to imatinib treatment | Q43779022 | ||
| Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. | Q43935639 | ||
| Cerebral oedema as a possible complication of treatment with imatinib | Q44017898 | ||
| Imatinib mesylate and gray hair | Q44094545 | ||
| Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia | Q44129015 | ||
| Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis | Q44161664 | ||
| Hypersensitivity pneumonitis related to imatinib mesylate | Q44178101 | ||
| Managing cutaneous reactions to imatinib therapy | Q44202316 | ||
| Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. | Q44291160 | ||
| Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population | Q44306071 | ||
| Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients | Q44312442 | ||
| A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). | Q44339633 | ||
| Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. | Q44358941 | ||
| Histological features of acute hepatitis after imatinib mesylate treatment | Q44443460 | ||
| Gynaecomastia in men with chronic myeloid leukaemia after imatinib | Q44474954 | ||
| Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa | Q44529440 | ||
| Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia | Q44548386 | ||
| Fatal hepatic necrosis following imatinib mesylate therapy | Q44625224 | ||
| Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia | Q44628909 | ||
| Ponatinib in refractory Philadelphia chromosome-positive leukemias | Q27851967 | ||
| Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias | Q28246193 | ||
| Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL | Q28246204 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia | Q29614280 | ||
| Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib | Q29999611 | ||
| Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati | Q30357011 | ||
| Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System | Q30884142 | ||
| Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. | Q30891587 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase | Q33358304 | ||
| Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence? | Q33365677 | ||
| Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance | Q33376325 | ||
| Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. | Q33379225 | ||
| Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia | Q33379934 | ||
| Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib | Q33381007 | ||
| Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy | Q33383664 | ||
| Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia | Q33384361 | ||
| Peripheral neuropathy as an adverse effect of imatinib therapy. | Q54616499 | ||
| Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib. | Q54641635 | ||
| Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. | Q55068849 | ||
| Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure | Q57731587 | ||
| Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib | Q58023728 | ||
| Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o | Q58023854 | ||
| Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy | Q58023949 | ||
| Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase | Q58023953 | ||
| UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia | Q58414397 | ||
| Reversible hair depigmentation in a patient treated with imatinib | Q58449048 | ||
| The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients | Q58847619 | ||
| Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia | Q59640192 | ||
| Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate | Q60021753 | ||
| Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. | Q64911638 | ||
| Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response | Q79372992 | ||
| In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' | Q79500683 | ||
| Corticosteroids can reverse severe imatinib-induced hepatotoxicity | Q79753992 | ||
| A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients | Q79797463 | ||
| Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia | Q80101748 | ||
| The Council of Europe recommendation Rec(2006)7 on management of patient safety and prevention of adverse events in health care | Q81812387 | ||
| A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib | Q82209172 | ||
| CML: how low can you go? | Q82431116 | ||
| Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study | Q83401553 | ||
| Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure | Q83622000 | ||
| Nilotinib-associated vascular events | Q84223022 | ||
| Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia | Q84481026 | ||
| Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice | Q84664163 | ||
| Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study | Q86419511 | ||
| Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity | Q86826642 | ||
| Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study | Q87171627 | ||
| In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' | Q94507897 | ||
| In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' | Q94507901 | ||
| In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' | Q94507905 | ||
| Practical management of tyrosine kinase inhibitor-associated side effects in GIST. | Q37767003 | ||
| Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients | Q37870181 | ||
| Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. | Q37917120 | ||
| Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. | Q37930709 | ||
| Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications | Q37977471 | ||
| Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization | Q38067464 | ||
| Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors | Q38087737 | ||
| Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. | Q38101103 | ||
| Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial | Q33384766 | ||
| The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. | Q33384822 | ||
| Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia | Q33387517 | ||
| Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase | Q33387519 | ||
| Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant | Q33390350 | ||
| Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia | Q33393383 | ||
| Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib | Q33394812 | ||
| Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase | Q33396120 | ||
| Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). | Q33398716 | ||
| Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia | Q33401360 | ||
| A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia | Q33402939 | ||
| Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. | Q33404602 | ||
| A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias | Q33411250 | ||
| Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients | Q33434455 | ||
| Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. | Q33729437 | ||
| Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia | Q33828570 | ||
| Periorbital edema secondary to imatinib mesylate | Q33867897 | ||
| Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. | Q33997854 | ||
| Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia | Q34022596 | ||
| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | Q34183674 | ||
| Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib | Q34210528 | ||
| Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion | Q34289635 | ||
| Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial | Q34297594 | ||
| Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). | Q34310190 | ||
| Severe adverse cutaneous reactions to drugs | Q34314152 | ||
| Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q34331941 | ||
| The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? | Q34412979 | ||
| Recommended standards for reports dealing with lower extremity ischemia: Revised version | Q34440231 | ||
| Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone | Q34508348 | ||
| Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. | Q34566073 | ||
| Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet | Q34567629 | ||
| Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia | Q34620246 | ||
| Congestive heart failure is a rare event in patients receiving imatinib therapy | Q34621382 | ||
| Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. | Q51373837 | ||
| Imatinib mesylate-induced interstitial pneumonitis | Q44684110 | ||
| Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). | Q44739628 | ||
| High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia | Q44834786 | ||
| Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase | Q44908385 | ||
| Imatinib mesylate causes hypopigmentation in the skin | Q44908400 | ||
| Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. | Q44993914 | ||
| Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st | Q45024357 | ||
| Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia | Q45148328 | ||
| Imatinib (Gleevec)-induced hepatotoxicity. | Q45187499 | ||
| Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib | Q45197239 | ||
| Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib | Q45227567 | ||
| How I treat leukemia during pregnancy | Q45286228 | ||
| Nilotinib post-liver transplantation for acute hepatic failure related to imatinib. | Q45919743 | ||
| Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy | Q45994559 | ||
| Hypolipemiant besides antileukemic effect of imatinib mesylate | Q46071343 | ||
| Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy | Q46084072 | ||
| Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia | Q46090252 | ||
| Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia | Q46104724 | ||
| Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party | Q46124555 | ||
| Pulmonary arterial hypertension in patients treated by dasatinib | Q46176185 | ||
| Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient | Q46185511 | ||
| Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia | Q46262660 | ||
| Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia | Q46332211 | ||
| Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). | Q46387826 | ||
| Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy | Q46453887 | ||
| An evaluation of the cardiotoxicity of imatinib mesylate | Q46583056 | ||
| Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia | Q46606987 | ||
| Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure | Q46614977 | ||
| Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells | Q46696380 | ||
| Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis | Q46709661 | ||
| Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib | Q46717583 | ||
| Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib | Q46775147 | ||
| Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss | Q46794206 | ||
| Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase | Q46797030 | ||
| Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. | Q46803794 | ||
| Conjunctival hemorrhagic events associated with imatinib mesylate. | Q46810398 | ||
| Imatinib and hyperlipidemia | Q46863520 | ||
| Imatinib mesylate as a cause of acute liver failure | Q46956777 | ||
| Patient-reported outcomes in acute leukemia: a roadmap for future research | Q48080881 | ||
| Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group | Q48449111 | ||
| European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted | Q48527068 | ||
| Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib | Q48906440 | ||
| Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling | Q49291505 | ||
| Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia | Q50998286 | ||
| The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia | Q51149470 | ||
| A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects | Q51371803 | ||
| Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy | Q51372022 | ||
| Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. | Q34639998 | ||
| Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial | Q34763374 | ||
| Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia | Q35008618 | ||
| Practical management of patients with chronic myeloid leukemia receiving imatinib | Q35095956 | ||
| Imatinib treatment: specific issues related to safety, fertility, and pregnancy | Q35143836 | ||
| Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. | Q35198387 | ||
| Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib | Q35265868 | ||
| Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina | Q35560018 | ||
| Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months. | Q35928884 | ||
| Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial | Q35930616 | ||
| Imatinib-induced fatal acute liver failure | Q36178243 | ||
| Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival | Q36370847 | ||
| Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. | Q36442499 | ||
| Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity | Q36447926 | ||
| High-Resolution Computed Tomography Findings for Patients With Drug-Induced Pulmonary Toxicity, With Special Reference to Hypersensitivity Pneumonitis-Like Patterns in Gemcitabine-Induced Cases | Q36804533 | ||
| Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies | Q36888547 | ||
| Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study | Q37025987 | ||
| European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. | Q37026032 | ||
| Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure | Q37027759 | ||
| Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia | Q37059387 | ||
| Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate | Q37068545 | ||
| Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet | Q37163550 | ||
| High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses | Q37163734 | ||
| Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily | Q37194640 | ||
| Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. | Q37287453 | ||
| A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib | Q37362975 | ||
| Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations | Q37385960 | ||
| Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor | Q37403026 | ||
| Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure | Q37470939 | ||
| Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature | Q37565808 | ||
| Cardiotoxicity induced by tyrosine kinase inhibitors | Q37593059 | ||
| Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation | Q37635609 | ||
| Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials | Q37642276 | ||
| Acute renal failure under dasatinib therapy | Q37683786 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International | Q24082749 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic myeloid leukemia | Q729735 |
| mechanism of action | Q3271540 | ||
| leukemia | Q29496 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1648-71 | |
| P577 | publication date | 2016-08-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia | |
| P478 | volume | 30 |
| Q57805096 | Q57805096 |
| Q57805112 | Q57805112 |
| Q57466761 | A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors |
| Q49929057 | Advancing a field by building consortia: The example of the European LeukemiaNet |
| Q43235803 | An overview of the role of platelets in angiogenesis, apoptosis and autophagy in chronic myeloid leukaemia. |
| Q64078547 | Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs |
| Q92501162 | Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart |
| Q90012698 | BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia |
| Q96640971 | Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study |
| Q52562694 | Bosutinib in chronic myeloid leukemia: patient selection and perspectives |
| Q47099925 | CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients |
| Q53129924 | Cardiologist's perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia |
| Q53276936 | Cardiovascular toxic effects of targeted cancer therapy |
| Q41348012 | Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance |
| Q90185523 | Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt) |
| Q51615048 | Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia |
| Q48509922 | Chronic Myeloid Leukemia: What Is the Best Strategy to Start and Monitor Treatment Outside Academic Centers? |
| Q48146023 | Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation |
| Q39061903 | Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia |
| Q47359410 | De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. |
| Q92759473 | De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial |
| Q54978822 | Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. |
| Q92868956 | Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation |
| Q60045225 | Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution |
| Q54979821 | Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. |
| Q53822299 | Divergent and Stereospecific Routes to Five to Eight-Membered 1,3- and 1,4-Di-Aza-Heterocycles via Ring-Opening Cyclization of Activated Aziridines with Aryl Amines |
| Q47094576 | Drug Repurposing for the Treatment of Acute Myeloid Leukemia |
| Q64228175 | Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients |
| Q50016898 | Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. |
| Q64287954 | Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells |
| Q90010384 | European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia |
| Q54977220 | Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes? |
| Q54119186 | Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. |
| Q94521558 | Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors |
| Q59796321 | Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients |
| Q94484014 | Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases |
| Q56967295 | Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial |
| Q30245010 | Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion |
| Q64074838 | Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV |
| Q91867290 | Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients |
| Q92715365 | Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line |
| Q53119368 | Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase |
| Q55339567 | In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers. |
| Q47113340 | Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia |
| Q33646189 | Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. |
| Q52648378 | Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases |
| Q92735773 | Is There a Role for Dose Modification of TKI Therapy in CML? |
| Q42279564 | Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate. |
| Q96230782 | Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study |
| Q95852568 | Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study |
| Q94076945 | MDR1和CYP3A5基因多态性对伊马替尼治疗慢性骨髓性白血病预后的影响 |
| Q92206177 | Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP |
| Q39411920 | Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors |
| Q57797259 | Molecular pathogenesis of leukemia and leukemic stem cells (LSCs) |
| Q64938069 | Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration. |
| Q33439536 | Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis |
| Q64991775 | Novel Score-based Decision Approach in Chronic Myeloid Leukemia Patients After Acute Toxic Imatinib-induced Liver Injury. |
| Q92022525 | Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice |
| Q54981978 | Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. |
| Q55362356 | Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. |
| Q90456937 | Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia |
| Q88913397 | Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study |
| Q103002088 | Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients |
| Q47877989 | Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series |
| Q52641875 | Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial |
| Q49553324 | Practical Management of Toxicities Associated With Bosutinib in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia |
| Q89710631 | Prospects for achieving treatment-free remission in chronic myeloid leukaemia |
| Q51368335 | Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. |
| Q38557421 | Recovering from chronic myeloid leukemia: the patients' perspective seen through the lens of narrative medicine |
| Q90738566 | Relationship of oxidative stress in the resistance to imatinib in Tunisian patients with chronic myeloid leukemia: A retrospective study |
| Q56961222 | Reply to Constance et al |
| Q42361988 | Research in the heart of hematology: chronic myeloid leukemia 2017. |
| Q55177555 | Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. |
| Q38789049 | Second line small molecule therapy options for treating chronic myeloid leukemia |
| Q47727670 | Severe liver toxicity in a chronic myeloid leukemia patient probably induced by a drug interaction between imatinib and sertraline |
| Q37512201 | Short overview on the current treatment of chronic myeloid leukemia in chronic phase |
| Q52715772 | Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib |
| Q54065188 | The DESTINY of chronic myeloid leukeamia |
| Q38642952 | The Safety of Bosutinib for the Treatment of Chronic Myeloid Leukemia |
| Q90029088 | The argument for using imatinib in CML |
| Q89776915 | The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia |
| Q64078772 | The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia |
| Q47159332 | The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity? |
| Q50997822 | Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop? |
| Q55005455 | Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence. |
| Q39423384 | Treatment-free remission in patients with chronic myeloid leukemia |
| Q95818691 | Two False Negative Test Results in a Symptomatic Patient with a Confirmed Case of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Suspected Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) |
| Q56977895 | Tyrosine Kinase Inhibitor Interruptions, Discontinuations and Switching in Patients with Chronic-Phase Chronic Myeloid Leukemia in Routine Clinical Practice: SIMPLICITY |
| Q92110376 | Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety |
| Q52567954 | Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making |
| Q92715817 | Tyrosine kinase inhibitor-induced carotid stenosis: A case report |
| Q30242015 | Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? |
| Q39226064 | Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection. |
| Q90710117 | WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors |
| Q49743400 | What is treatment free remission in chronic myeloid leukemia? |
| Q88150038 | [How I treat newly diagnosed chronic myeloid leukemia in chronic phase] |
Search more.